Filter Your Search

Clinical Trial Search

Keyword

Principal Investigator

Condition/Disease

For Healthcare Professionals

At Henry Ford Health we serve a triple mission of Clinical Care, Research and Education. It is this triple mission that drives how we care for our patients, how we interact with referring physicians, how we work to innovate healthcare and how we train future physicians.

Learn More

Clinical Trials Search Results

MK4830-001: A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

Principal Investigator:unassigned

Status: Open

Contact Phone: (313) 916-7450

Contact Email: [email protected]

PTC-299-HEM-001-LEU: Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

Principal Investigator:Ahmad H Mattour, MD

Status: Accepting Participants

Contact Phone: (888) 734-5322

Contact Email: [email protected]

GBM 001: An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma

Principal Investigator:Tobias Walbert, MD

Status: Accepting Participants

Contact Phone: (313) 916-3731

Contact Email: [email protected]

RPC-1063-MS-001: A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod

Principal Investigator:Anza B Memon, MD

Status: Accepting Participants

Contact Phone: 313-916-1482

Contact Email: [email protected]

MS200527-0018 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Principal Investigator:Kathleen M Maksimowicz-Mckinnon, DO

Status: Accepting Participants

Contact Phone: (313) 916-9328

Contact Email: [email protected]

ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Principal Investigator:unassigned

Status: Accepting Participants

Contact Phone: (313) 916-1784

Contact Email: [email protected]

MK-7339-010 - A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: [email protected]

Astellas 8374 CL 01010

Principal Investigator:unassigned

Status: Open

Contact Phone: 1-888-734-5322

Contact Email: [email protected]

INCB 01158-101:Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Principal Investigator:unassigned

Status: In Progress

Contact Phone: (313) 916-7450

Contact Email: [email protected]

AROG Pharmaceuticals ARO-013, Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Principal Investigator:Yue Guo, MD

Status: Accepting Participants

Contact Phone: (313) 916-1784

Contact Email: [email protected]

Page 1 of 27 | Results 1 - 10 of 261

Browse Locations by Type Search All Locations

Frequently Searched ServicesSearch All Services

Browse Services by A-Z

Connect with Us

Resources

Research & Education

Clinical Trial Search

For Healthcare Professionals

Clinical Trials Search Results

MK4830-001: A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

PTC-299-HEM-001-LEU: Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

GBM 001: An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma

RPC-1063-MS-001: A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod

MS200527-0018 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Astellas 8374 CL 01010

INCB 01158-101:Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

AROG Pharmaceuticals ARO-013, Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Browse Locations by Type Search All Locations

Frequently Searched ServicesSearch All Services

Browse Services by A-Z

Connect with Us

Resources

Research & Education

Clinical Trial Search

For Healthcare Professionals

Clinical Trials Search Results

Consent for Cookie Use